The stock is in a clear downtrend over the past three months, with a 1-year price change of +30.2% but a 3-month decline of -28.6%. Currently trading at $8.83, it sits at 23.5% of its 52-week range ($5.77 low to $18.78 high), near the low end, suggesting a potential value opportunity but also reflecting bearish sentiment. The 1-year gain is misleading as the stock has given back most of its earlier rally, now 53% below the 52-week high. Short-term momentum is decisively negative: the 1-month change is -19.0%, and the 3-month change is -28.6%, both underperforming the S&P 500 (1-month +4.1%, 3-month +11.1%). The relative strength indicators (1-month -23.0%, 3-month -39.7%) confirm severe underperformance. This divergence from the 1-year trend signals a potential trend reversal or a temporary pullback, but the persistent selling pressure suggests caution. The 52-week low at $5.77 provides key support; a breakdown below that level would signal further downside, while resistance is at the 52-week high of $18.78. A breakout above $18.78 would indicate a resumption of the uptrend. Beta is 1.30, meaning the stock is 30% more volatile than the market, amplifying both gains and losses, which is critical for risk management.

Revenue has grown significantly but from a small base: the most recent quarter (Q3 fiscal 2026, ended Dec 2025) reported revenue of $26.2 million, up 18.7% year-over-year from $13.3 million in the prior-year quarter. However, the trajectory shows deceleration from the prior quarter's $9.6 million (Q2) and $3.2 million (Q1), indicating lumpy revenue typical of government contracts. The full-year revenue run rate is still modest, and the company remains pre-revenue in terms of profitability. The company is unprofitable, with a net loss of -$19.7 million in the latest quarter and a net margin of -74.9%. Gross margin improved to 4.2% from negative levels a year ago, but remains razor-thin, reflecting high cost of goods sold ($25.1 million vs. $26.2 million revenue). Operating margin was -91.3%, indicating heavy spending on R&D ($4.9 million) and SG&A ($20.2 million). The company has a strong balance sheet with $167.9 million in cash and minimal debt (debt-to-equity of 0.075). However, free cash flow is deeply negative at -$41.9 million in the latest quarter, and the company relies on equity financing (common stock issued $3.3 million in Q3) to fund operations. ROE is -29.3%, reflecting persistent losses. The high current ratio of 15.3 suggests ample liquidity, but the cash burn rate is unsustainable without continued capital raises or a path to profitability.